Mease, P. J., Gladman, D. D., Strand, V., Vlam, K. d., Covarrubias-Cobos, J. A., Cappelleri, J. C., . . . Wu, J. (2019). Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. BMJ Publishing Group.
Chicago Style (17th ed.) CitationMease, Philip J., et al. Effect of Tofacitinib on Patient-reported Outcomes in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond. BMJ Publishing Group, 2019.
MLA (9th ed.) CitationMease, Philip J., et al. Effect of Tofacitinib on Patient-reported Outcomes in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond. BMJ Publishing Group, 2019.